A practical reference on peptide analogue: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-21. Anything still debated is marked as such rather than presented as settled.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
Beyond p53, in cancer, many oncogenes and tumor suppressors have been discovered to be SUMOylated in order for the cancer to progress or not, with each SUMOylation event having one of a variety of effects. When IκB is SUMOylated, the SUMO post-translational modification outcompetes ubiquitination, protecting it from degradation, and by extension, the transcription factor NF-κB is bound in a complex with IκB, preventing the expression of genes that may otherwise cause cells with DNA damage to apoptose. In hypoxic conditions as arise in some cancers, HIF-1α, which is usually SUMOylated followed by subsequent ubiquitination and degradation through the von Hippel-Lindau tumor suppressor's ubiquitin ligase activity, is instead deSUMOylated thereby promoting survival of the tumorigenic cells. The fallout from deSUMOylation of HIF-1α includes promotion of MMPs which are understood to contribute to the progression of EMT, a hallmark of cancer. In atherosclerosis, both p53 and ERK5 are SUMOylated by the stimulus of disturbed blood flow. The stimulus is transduced by the activation of a serine/threonine kinsase called p90RSK, which phosphorylates the human SUMO protease SENP2 at the throenine amino acid residue 368. That phosphorylation is sufficient for the delocalization of the SENP2 from the nucleus. The effects of this phosphorylation-dependent SENP2 inhibition by nuclear export include the SUMOylation of p53 which leads to endothelial cell apoptosis, and SUMOylation of ERK5 which leads to inflammation.
==== Forensic applications ==== The GC-EI-MS is also used in forensic science. One example is the analysis of five local anesthetics in blood using headspace solid-phase microextraction (HS-SPME) and gas chromatography–mass spectrometry–electron impact ionization selected ion monitoring (GC–MS–EI-SIM). Local anesthesia is widely used but sometimes these drugs can cause medical accidents. In such cases an accurate, simple, and rapid method for the analysis of local anesthetics is required. GC-EI-MS was used in one case with an analysis time of 65 minutes and a sample size of approximately 0.2 g, a relatively small amount. Another application in forensic practice is the determination of date rape drugs (DRDs) in urine. These drugs are used to incapacitate victims and then rape or rob them. The analyses of these drugs are difficult due to the low concentrations in the body fluids and often a long time delay between the event and clinical examination. However, using GC-EI-MS allows a simple, sensitive and robust method for the identification, detection and quantification of 128 compounds of DRDs in urine.
According to Rubio, the first phase is about the stabilization of the country after the strikes and stopping it from "descending into chaos," including refining and selling up to 50 million barrels of seized Venezuelan crude oil, adding that "that money will then be handled in such a way that we will control how it is disbursed in a way that benefits the Venezuelan people, not corruption, not the regime, so we have a lot of leverage to move on the stabilization front." During the second phase of recovery, the goal is to assure foreign companies have access to Venezuelan oil trade and "also, at the same time, begin to create the process of reconciliation nationally within Venezuela, so that the opposition forces can be amnestied and released from prisons or brought back to the country, and begin to rebuild civil society." Rubio added that the final and third phase consist on overseeing a transition, "this will be a process of transition. In the end, it will be up to the Venezuelan people to transform their country." Trump stated there was an agreement by Venezuela to deliver a few months' worth of oil to the US, intimating that other steps, such as the freeing of political detainees and a role for the exiled opposition, might be next. However, President Rodríguez denied the existence of a deal, saying "no external agent" was dictating her decisions. On 8 January, the US Senate voted 52 to 47 to advance a war resolution that aimed to block the president's use of the US military to engage in military action within or against Venezuela unless authorized by Congress.
In Winter 1996, Kenyon's co-authored paper, "The RNA World: A Critique," appeared in Origins and Design, a now defunct creationist journal where he was on the Editorial Advisory Board. He continued publicly arguing in favor of creationism, notably at the 1998 International Conference on Creationism. Currently, Kenyon is a speaker, writer, and board member for the Kolbe Center, a Catholic YEC group. In 2008, Kenyon endorsed a young Earth creationist book promoted by the Center.
Sources: en.wikipedia.org
An overdose of benzodiazepines can cause dangerous deep unconsciousness, but are less toxic than their predecessors, the barbiturates, and death rarely results when a benzodiazepine is the only drug taken. Combined with other central nervous system (CNS) depressants such as alcohol and opioids, the potential for toxicity and fatal overdose increases significantly. Flumazenil is generally considered a first-line treatment in benzodiazepine overdose, although its usage outside the controllable environment of medical facilities possesses great risk of developing seizures and other life-threating conditions. Benzodiazepines are commonly used recreationally and also often taken in combination with other addictive substances, and are controlled in most countries.
=== Election to the presidency === On May 30, 2016, the 16th Congress of the Philippines proclaimed Duterte as the president-elect of the Philippines after he topped the official count by the Congress of the Philippines for the 2016 presidential election with 16,601,997 votes, 6.6 million more than his closest rival, Mar Roxas. Camarines Sur representative Leni Robredo on the other hand, was proclaimed as the vice president-elect of the Philippines with 14,418,817 votes, narrowly defeating Senator Bongbong Marcos by 263,473 votes. Duterte's election victory was attributed to growing public dissatisfaction on the perceived failures of administrations that followed the 1986 EDSA Revolution. It was also aided by a strong social media and grassroots fanbase and the endorsement of the influential Iglesia ni Cristo, known for its block-voting.
== External links == Safety MSDS data Mohajer, Fatemeh; Mohammadi Ziarani, Ghodsi (2021). "An Overview of Quantitative and Qualitative Approaches on the Synthesis of Heterocyclic Kojic Acid Scaffolds through the Multi-Component Reactions". Heterocycles. 102 (2). Japan Institute of Heterocyclic Chemistry: 211. doi:10.3987/REV-20-936.
Sources: en.wikipedia.org
=== Theft === Radioactive materials in RTGs are dangerous and can be used for malicious purposes. They are not useful for a genuine nuclear weapon, but still can serve in a "dirty bomb". The Soviet Union constructed many uncrewed lighthouses and navigation beacons powered by RTGs using strontium-90 (90Sr). They are very reliable and provide a steady source of power. Most have no protection, not even fences or warning signs, and the locations of some of these facilities are no longer known due to poor record keeping. In one instance, the radioactive compartments were opened by a thief. In another case, three woodsmen in Tsalenjikha Region, Georgia found two ceramic RTG orphan sources that had been stripped of their shielding; two of the woodsmen were later hospitalized with severe radiation burns after carrying the sources on their backs, and the third died. The units were eventually recovered and isolated. There are about 1,000 such RTGs in Russia, all of which have long since exceeded their designed operational lives of ten years. Most of these RTGs likely no longer function, and may need to be dismantled. Some of their metal casings have been stripped by metal hunters, despite the risk of radioactive contamination. Transforming the radioactive material into an inert form reduces the danger of theft by people unaware of the radiation hazard (such as happened in the Goiânia accident in an abandoned Cs-137 source where the caesium was present in easily water-soluble caesium chloride form).
==== Usage in global industry ==== Direct oxidation of ethylene was patented by Lefort in 1931. This method was repeatedly modified for industrial use, and at least four major variations are known. They all use oxidation by oxygen or air and a silver-based catalyst, but differ in the technological details and hardware implementations. Union Carbide (currently a division of Dow Chemical Company) was the first company to develop the direct oxidation process. A similar production method was developed by Scientific Design Co., but it received wider use because of the licensing system – it accounts for 25% of the world's production and for 75% of world's licensed production of ethylene oxide. A proprietary variation of this method is used by Japan Catalytic Chemical Co., which adapted synthesis of both ethylene oxide and ethylene glycol in a single industrial complex. A different modification was developed Shell International Chemicals BV. Their method is rather flexible with regard to the specific requirements of specific industries; it is characterized by high selectivity with respect to the ethylene oxide product and long lifetime of the catalyst (3 years). It accounts for about 40% of global production. Older factories typically use air for oxidation whereas newer plants and processes, such as METEOR and Japan Catalytic, favor oxygen.
He continued updating this publication to 2010, and it with its research documents and notes, including about half a million press cuttings, is now archived at the Bishopsgate Institute. William Rothenstein (29 January 1872 – 14 February 1945), painter, printmaker, draughtsman, lecturer, writer on art; wrote several critical books and pamphlets, including Goya; the first English monograph on the artist), A Plea for a Wider Use of Artists & Craftsmen and Whither Painting; published three volumes of memoirs: Men and Memories, Vol I and II and Since Fifty. Men and Memories Volume I includes anecdotes about Oscar Wilde and many other friends of Rothenstein's, including Max Beerbohm, James Whistler, Paul Verlaine, Edgar Degas, and John Singer Sargent. Hannah Rothschild (born 22 May 1962), daughter of Jacob Rothschild, 4th Baron Rothschild, author, businesswoman, philanthropist and documentary filmmaker, has written screenplays and journalism, a biography and two novels; serves on charitable and financial boards and is first female to chair the Board of Trustees of the National Gallery in London;liaison trustee for the Tate Gallery;trustee of the Whitechapel Gallery;chair of Yad Hanadiv in Israel; directed films for Saturday Review, Arena and Omnibus; has written for The Times, The New York Times, The Observer, The Guardian, Daily Telegraph, Vanity Fair, Vogue, The Spectator and Harper's Bazaar, Financial Times, Elle, Washington Post and others.
The Aga Khan University Hospital (AKUH) is a private hospital in Karachi, Pakistan. Established in 1985, it is the primary academic medical centre of the Aga Khan University. The hospital provides quaternary care, including multidisciplinary care across all clinical specialities.[1]
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.